All In Biotech

NDA 017100 · Abbvie

Pred Mild

Prednisolone Acetate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1972

Nov 10, 1972

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,078

579 Phase 3, 236 recruiting

FAERS reports

8,532

4,015 serious, 456 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 25, 2025.

INDICATIONS AND USAGE PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 10, 1972 Original approval · Type 3 - New Dosage Form
1 products under this application
  • PRED MILD · PREDNISOLONE ACETATE 0.12% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Prednisolone" as an intervention, any sponsor and status, largest first.

All 2,078 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,252
  • drug ineffective777
  • recalled product administered763
  • no adverse event651
  • off label use554
  • eye pain482
  • eye irritation320
  • vision blurred287
  • fatigue261
  • headache241
  • diarrhoea225
  • condition aggravated210

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200531
200635
200770
2008131
200952
201075
201170
2012165
201394
2014131
2015247
2016489
2017282
2018412
2019482
20201,641
2021439
2022510
2023596
2024631
2025673
20261,259

Recalls

1 FDA enforcement reports for this application.

  • May 18, 2026 · Class III · Ongoing

    Failed Stability Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pred Mild (Prednisolone Acetate)

2024 spending

$735K

Beneficiaries

1,779

3,319 claims

Per beneficiary

$413

$32.10 per unit

View as table
YearSpending
2020$1,225,909
2021$1,096,073
2022$982,555
2023$799,205
2024$734,883

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,677 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.